AwardedSpainGoods€157,259,011
Suministro de medicamentos de uso humano que contiene los principios activos siguientes: Vemurafenib, Dornasa Alfa, Vismodegib, Cobimetinib, Alectinib, Emicizumab, Polatuzumab, Pertuzumab/Trastuzumab, Risdiplam, Faricimab, Entrectinib y Satralizumab a través del procedimiento negociado sin publicidad por exclusividad.
- Published
- Published 14 July 2025
Overview
Suministro de medicamentos de uso humano que contiene los principios activos siguientes: Vemurafenib, Dornasa Alfa, Vismodegib, Cobimetinib, Alectinib, Emicizumab, Polatuzumab, Pertuzumab/Trastuzumab, Risdiplam, Faricimab, Entrectinib y Satralizumab a través del procedimiento negociado sin publicidad por exclusividad.
Key details
- Country
- Spain
- Status
- Awarded
- Category
- Goods
- Estimated value
- €157,259,011
- Procedure
- Direct
- Published
- 14 July 2025
AntihaemorrhagicsMedicinal products for the musculo-skeletal systemAntineoplastic agentsImmunosuppressive agentsOphthalmologicalsCough and cold preparations
Award outcome
- Awarded value
- €37,442,622
- Award date
- 12 June 2025
- ROCHE PHARMA, S.A.
Contract ending soon? Skim tracks incumbents and flags recompetes early. Book a demo to set up alerts.
Notice history
Every published notice in this contracting process, newest first.
Contract Award Notice
14 July 2025
Contracting authority
Dirección General de Gestión Económica, Contratación e Infraestructuras de la Conselleria de Sanidad
Procuring entityValencia, Spain
ID_PLATAFORMA: 20897030133463
Get the full picture
AI analysis, bid scoring, and expert strategy for this tender
Skim analyses every tender against your company profile and tells you whether to bid, how to win, and who you are up against.
See which competitors are winning the contracts you're chasing.
15-minute call. We'll pull the win data on your real pipeline and show you what Skim does with it.